Les grandes entreprises face à la révolution biotechnologique

Abstract

Corporates face biotech revolution. Big corporations account for an increasingly large share of the R&D budget as regards biotechnologies. Their own constraints would seem to have led them to slow down rather than accelerate the applications of these new techniques. This could continue to be the case as long as the "Fordist" options that until now have influenced agricultural growth have not been called into question. The new research options could thereafter allow for a gradual change in the prédominant technological paradigms.